医药商业公司大洗牌

赛柏蓝
Oct 01

特约作者 | 董泽成责任编辑 | 郑瑶盈利能力降低;回款差;合规要求高,运营风险与日俱增,多重因素作用下,医药商业公司面临前所未有的困境,一场大整合或在所难免。01国内医药商业公司还剩哪几类?截至2024年底,国内医药商业公司大约有1.48万家,和2023年的1.32万家相比不减反增。首先是头部商业公司的子公司数量占比高。国药控股1100多家分子公司,九州通子公司687家,华润医药470余家分子...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10